Company
COMPANY
About ADEL
ADEL, Inc. was established in 2016 and is a SPIN-off company at Asan Hospital in Ulsan Medical School,
aimed at developing neuropathic treatments and diagnostic systems such as Alzheimer’s disease.
ADEL
We dream of a world
without dementia
ADEL, Inc.
- CEO
- Seung-Yong Yoon
- Establishment date
- November 10, 2016
- Business Areas
- Alzheimer's disease & Dementia treatment and diagnostic method
- Location
- Headquarters:
Dep of Brain Science, AMC, 88, Olympic-ro 43-gil, Songpa-gu, Seoul
Seongnae Lab:
HANS building 3F & 5F, 90, Pungseong-ro, Gangdong-gu, Seoul
Gwanggyo Lab:
A-711&712, 338, Gwanggyojungang-ro, Suji-gu, Yongin-si, Gyeonggi-do
- Number of employees
- 20 people (October 2023)
- R&D personnel
- 15 people (October 2022)
CEO
Seung-Yong YoonMD, PhD.
- CEO of ADEL
- Chief Professor at the Department of Brain Science, Asan Medical Center, University of Ulsan College of Medicine
- Director of Brain Neuroscience Research Team, Asan Institute for Life Sciences
- Bachelor's, Master's, and Doctorate degrees in Medicine from Ulsan University School of Medicine
- 20 years of experience in Alzheimer's disease research and development
- Author of over 70 SCI papers and holder of over 10 patents
- Career spanning the entire research and development process (Basic-CMC-Preclinical-Clinical)
- Success in technology transfer and collaborative research commercialization
Organization
HISTORY
-
2023
- US FDA Ph1 IND (Y01)
- Addition of pipelines
-
2020
- Series B
- Contract with Co-development partner (Oscotec, Inc)
-
2018
- Series A
-
2016
- ADEL, Inc. establishment